# Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer

> **NCT03957902** · PHASE2 · RECRUITING · sponsor: **Instituto de Investigación Sanitaria Aragón** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** acetylsalicylic acid

## Key facts

- **NCT ID:** NCT03957902
- **Lead sponsor:** Instituto de Investigación Sanitaria Aragón
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-05-06
- **Primary completion:** 2025-05
- **Final completion:** 2025-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957902, "Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03957902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*